Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.

Treatment (Antiangiogenesis Therapy)

Sex: Female, Male

Region of Enrollment

'Activity' will be operationalized using objective tumor response, which will be estimated as the proportion of partial and complete responders (according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria) among all evaluable patients. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response

See the adverse event tables for specifics.

Number of Participants Who Experienced Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

Time to Disease Progression

Overall Survival

Plasma Levels of Angiogenic Peptides Including Placental Growth Factor (PlGF)

Patients receive therapeutic angiotensin-(1-7) subcutaneous (SC) once daily in the absence of disease progression or unacceptable toxicity.

Overall Study

Dr. William J. Petty

Bone Cancer

Chondrosarcoma

Clear Cell Sarcoma of the Kidney

Metastatic Osteosarcoma

Ovarian Sarcoma

Recurrent Adult Soft Tissue Sarcoma

Recurrent Osteosarcoma

Recurrent Uterine Sarcoma

Stage III Adult Soft Tissue Sarcoma

Stage III Uterine Sarcoma

Stage IV Adult Soft Tissue Sarcoma

Stage IV Uterine Sarcoma

therapeutic angiotensin-(1-7)

laboratory biomarker analysis

Wake Forest University Health Sciences

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas

National Cancer Institute (NCI)

Dermatologic Diseases

skin tissue sample

Beckman Laser Institute Medical clinic

Gottschalk Medical Plaza

Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

Evaluate the role of angiogenesis in cutaneous disease and ultimately, facilitate implementation of anti-angiogenic therapy in a wide range of dermatologic diseases including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea and psoriasis.

angiotensin/sarcóma

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht